Hypertrophic Cardiomyopathy Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034

Hypertrophic Cardiomyopathy Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034

The 7 major hypertrophic cardiomyopathy markets reached a value of US$ 312.5 Million in 2023. Looking forward, IMARC Group expects the 7MM to reach US$ 356.7 Million by 2034, exhibiting a growth rate (CAGR) of 1.21% during 2024-2034.

The hypertrophic cardiomyopathy market has been comprehensively analyzed in IMARC's new report titled "Hypertrophic Cardiomyopathy Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Hypertrophic cardiomyopathy refers to a condition in which the cardiac muscle becomes abnormally thick. The parts of the heart most frequently affected are the ventricles and the interventricular septum. This can make the heart walls stiff and reduce its ability to pump blood effectively, resulting in electrical conduction problems. Individuals suffering from the disease may experience fatigue, leg swelling, shortness of breath, chest pain, fainting, etc. The other common symptoms of hypertrophic cardiomyopathy include abnormal heart rhythms (arrhythmias), dizziness, lightheadedness, etc. These indications may be worse if a person is dehydrated. The diagnosis of the ailment is typically made using the medical history and underlying symptoms of the patient, along with a physical exam and laboratory tests. The healthcare provider may also perform numerous diagnostic procedures, such as an electrocardiogram, cardiac magnetic resonance imaging, echocardiogram, etc. Additionally, stress tests and genetic testing can be utilized to confirm a diagnosis among patients.

The rising cases of inherited genetic mutations that affect the proteins in heart muscle cells are primarily driving the hypertrophic cardiomyopathy market. In addition to this, the elevating incidences of several associated risk factors, including sedentary lifestyle, obesity, aging, high blood pressure, intense endurance exercise, etc., are further augmenting the market growth. Moreover, the emerging popularity of effective medications, such as beta-blockers, calcium channel blockers, diuretics, etc., for reducing the heart's workload and improving blood flow among patients is also creating a positive outlook for the market. Apart from this, the widespread adoption of transesophageal echocardiogram (TEE), which utilizes sound waves to create a superior quality image of the heart structures with greater depth and provide confirmed disease diagnosis, is further bolstering the market growth. Additionally, the escalating utilization of alcohol septal ablation, a non-surgical procedure, to treat the condition by injecting alcohol into one or more septal branches of the left anterior descending artery, is acting as another significant growth-inducing factor. Besides this, the rising usage of implantable cardioverter defibrillator therapy that can prevent sudden death in patients with an increased risk of ventricular arrhythmias, is expected to drive the hypertrophic cardiomyopathy market in the comipng years.

IMARC Group's new report provides an exhaustive analysis of the hypertrophic cardiomyopathy market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for hypertrophic cardiomyopathy and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the hypertrophic cardiomyopathy market in any manner.

Time Period of the Study

Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034

Countries Covered

United States
Germany
France
United Kingdom
Italy
Spain
Japan

Analysis Covered Across Each Country

Historical, current, and future epidemiology scenario
Historical, current, and future performance of the hypertrophic cardiomyopathy market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the hypertrophic cardiomyopathy market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current hypertrophic cardiomyopathy marketed drugs and late-stage pipeline drugs.

In-Market Drugs

Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance

Late-Stage Pipeline Drugs

Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance

Drugs Company Name
Camzyos (Mavacamten) Britol Myers Squibb/MyoKardia
CK 3773274 Cytokinetics
IMB-1018972 Imbria Pharmaceuticals
LCZ696 Novartis

*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

Key Questions Answered in this Report:
Market Insights

How has the hypertrophic cardiomyopathy market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the hypertrophic cardiomyopathy market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the hypertrophic cardiomyopathy market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?

Epidemiology Insights

What is the number of prevalent cases (​2018-2034​) of hypertrophic cardiomyopathy across the seven major markets?
What is the number of prevalent cases (​2018-2034​) of hypertrophic cardiomyopathy by age across the seven major markets?
What is the number of prevalent cases (​2018-2034​) of hypertrophic cardiomyopathy by gender across the seven major markets?
How many patients are diagnosed (​2018-2034​) with hypertrophic cardiomyopathy across the seven major markets?
What is the size of the hypertrophic cardiomyopathy patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of hypertrophic cardiomyopathy?
What will be the growth rate of patients across the seven major markets?

Hypertrophic Cardiomyopathy: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for hypertrophic cardiomyopathy drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the hypertrophic cardiomyopathy market?
What are the key regulatory events related to the hypertrophic cardiomyopathy market?
What is the structure of clinical trial landscape by status related to the hypertrophic cardiomyopathy market?
What is the structure of clinical trial landscape by phase related to the hypertrophic cardiomyopathy market?
What is the structure of clinical trial landscape by route of administration related to the hypertrophic cardiomyopathy market?